Marty Makary: Is the First Good Pick for FDA commissioner in a long time
Why I like Marty & how the media is biased
Related Articles
BellissiMo’s Mo Space
Movember, the month formerly known as November, is a moustache growing charity event held during November each year that raises funds and awareness for men’s…
“Nailing down” risk and improving outcomes in early-stage breast cancer
Whether via the strain of academic advancement or hyper-competitive industry-funded drug-development landscape,1 there has been increasing focus to shift c
Medicare’s New Pathway for Transitional Coverage for Emerging Technologies
This Viewpoint discusses the Centers for Medicare & Medicaid Services Transitional Coverage for Emerging Technologies pathway.
Home | Ask Doctor Ed
He’s called Dr. Ed — that’s Edward T. Creagan, MD, a cancer specialist, the first Mayo Clinic doctor board certified in hospice and palliative medicine.…
The Secrets of Great Teamwork
Over the years, as teams have grown more diverse, dispersed, digital, and dynamic, collaboration has become more complex. But though teams face new challenges, their…
Psychiatrist: Why I oppose Leadbeater’s Bill – Better Way
Professor Allan House When MP Kim Leadbeater published her recent private members bill, which aims to decriminalise assisted suicide under certain criteria, she announced that it…
Are calories on menus doing more harm than good?
Many restaurants in countries such as England and the US now print calories on their menus, but some researchers question whether this is really tackling…
MYASTHENIA GRAVIS IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS
Immune checkpoint inhibitors have improved outcomes significantly for patients across multiple tumor types, and now are being used in combination with other therapies and in…
Marty Makary: Is the First Good Pick for FDA commissioner in a long time
Why I like Marty & how the media is biased